The global Crohn’s disease drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to accelerate the growth of the market include the increasing incidence of inflammatory bowel syndrome, such as Crohn’s disease and ulcerative colitis. This is boosting the demand for anti-inflammatory drugs for the treatment of Crohn’s disease. Some kinds of anti-inflammatory medications that are used used to treat Crohn's disease include 5 aminosalicylic acid (5-ASA) compounds, such as mesalamine (Pentasa, Canasa suppository) and sulfasalazine (Azulfidine). These work in direct contact or they can be applied topically with the inflamed tissue which makes healing effective. 

Another factor that is creating a positive impact on this segment is the fact that there is no permanent cure for Crohn’s disease. Technically, Crohn’s disease has no permanent cure and therefore patients suffering from this particular disease and its associated conditions have to depend on anti-inflammatory and other drugs to obtain relief. Crohn's disease is a type of inflammatory bowel disease (IBD). It causes inflammation of digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people. This inflammation often spreads into the deeper layers of the bowel.

Crohn’s disease drug manufacturers are focusing on the commercial distribution of medicines through retail pharmacies and online portals. These channels widely distribute anti-inflammatory drugs and corticosteroids with and/or without prescription. Consumers can also avail of discounts on bulk purchases of medicines through online portals. Therefore, easy product availability, as well as price discounts, contribute significantly to the growth of the market. Further, in order to maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships and collaborations, and mergers and acquisitions. In September 2021, AbbVie, Inc. ABBV announced that it has submitted a regulatory application in the US, seeking approval for its interleukin-23 (“IL-23”) inhibitor Skyrizi (risankizumab) as a potential treatment for moderate to severe Crohn’s disease (CD). It seeks approval for Skyrizi both as a 600mg intravenous (“IV”) induction and 360mg subcutaneous maintenance therapy in patients aged 16 years and older with CD.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drug Type 

o By Route of Administration

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape: Allergan plc, AbbVie Inc., and Pfizer Inc., among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Crohn’s Disease Drugs Market Report by Segment

By Drug Type

• Anti-Inflammatory
• Immune System Suppressors
• Antibiotics
• Others

By Route of Administration

• Oral
• Injectable

Global Crohn’s Disease Drugs Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa